Form 4: Whitehawk Therapeutics Director Receives Significant Stock Option Grant

Mohammad Hirmand, a Director at Whitehawk Therapeutics, Inc., was granted 40,006 stock options with an exercise price of $2.04, aligning his interests with the company's long-term performance.

Summary

• Mohammad Hirmand, a Director of Whitehawk Therapeutics, Inc. (WHWK), was granted 40,006 stock options on June 12, 2025.
• The stock options have an exercise price of $2.04 per share.
• The options are subject to a vesting schedule where 100% of the shares will vest on the earlier of the one-year anniversary of the grant date (June 12, 2025) or the day immediately prior to the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Hirmand continuing to be a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• The granted options have an expiration date of June 12, 2035.
• Following this transaction, Mr. Hirmand directly beneficially owns 40,006 derivative securities (stock options).
• Mr. Hirmand also executed a Power of Attorney on April 25, 2025, authorizing specific individuals to handle his SEC filings related to Whitehawk Therapeutics securities.

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction (stock option grant) which is generally a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative financial implications or significant risks disclosed beyond the standard vesting conditions.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The vesting schedule encourages the director's continued service and commitment to the company's strategic objectives.
• The Power of Attorney streamlines the director's compliance with complex SEC reporting requirements.

Risks

• The vesting of the stock options is conditional on the reporting person continuing to be a 'Service Provider,' meaning the options may not fully vest if the service relationship ceases before the vesting conditions are met.
• The Power of Attorney explicitly states that neither the Company nor the Attorney-in-Fact assumes liability for the undersigned's responsibility to comply with SEC reporting requirements or for disgorgement of profits under Section 16(b) of the Exchange Act, placing the ultimate compliance burden on the reporting person.

Future Outlook

The stock options are subject to a future vesting schedule, with 100% vesting on the earlier of the one-year anniversary of the June 12, 2025 grant date or the day prior to the next annual meeting of stockholders, contingent on the director's continued service.

Industry Context

Granting stock options to directors is a common practice across industries to incentivize long-term commitment and align their interests with those of shareholders. This filing indicates standard corporate governance practices for executive and director compensation within publicly traded companies.

Comparison to Industry Standards

• The grant of 40,006 stock options to a director is a typical form of non-cash compensation, aligning with common practices for incentivizing board members in publicly traded companies.
• The exercise price of $2.04, if reflective of the market price on the grant date, is standard for such awards.
• The vesting schedule (one year or next annual meeting) is a common approach for director equity awards, designed to encourage retention and align interests over a reasonable period, consistent with practices observed in companies of similar size and sector.

Corporate Governance

Related Party Transactions

• The grant of 40,006 stock options to Mohammad Hirmand, a Director of Whitehawk Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• **Shareholders**: The grant of stock options aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases. However, it also represents potential future dilution if the options are exercised.
• **Employees**: The document does not directly impact general employees, but the reference to 'Service Provider' in the vesting terms indicates the director is considered an important contributor.
• **Management**: The Power of Attorney designates specific individuals within the company (or related to it) to manage the director's SEC filings, indicating internal support for compliance and administrative efficiency.

Next Steps

• The granted stock options will vest according to the specified schedule, contingent on the director's continued service.
• Mohammad Hirmand will continue to be subject to SEC reporting requirements under Section 16 of the Securities Exchange Act of 1934.

Key Dates

Recommendation

Keywords

Whitehawk Therapeutics, WHWK, Mohammad Hirmand, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Corporate Governance